14-Center Study Confirms Effectiveness of Aller-7 in 545 People With Airborne Allergies

14-Center Study Confirms Effectiveness of Aller-7 in 545 People With Airborne Allergies Multicenter clinical trial spanning three years and involving 545 patients in 14 clinical centers confirms the safety and efficacy of Aller-7(R) in people with allergic rhinitis.
Home Naturade Significantly Strengthens Balance Sheet; Receives $2.5 Million in Capital from Westgate Equity Partners, L.P. Natrol Appoints Vincent Andrich VP Sales for Prolab Division Vermont Pure Holdings, Ltd. Announces Record Fiscal Year 2001 Results Body Shop Reports 24.8 Mil Euro Sales Revenues Spectrum Organic Products Responds to FDA Letter Regarding Use of Non-GMO Seal on Canola Oil Label Supplement Group Targets Consumer Education Advanced Nutraceuticals, Inc. Announces 2001 Year End Results And Additional Financing ADM Awarded Nutraceuticals Patent Patent Creates Proprietary Position for ADM in Fast-Growing Nutraceutical Market Tantivy Sciences Obtains Exclusive License to Unique Nutraceutical Products Top GNC Executives Tour Pittsburgh Market to Present New Business Plan and Expansion Possibilities; Meeting will focus on new business strategies and growth Nutrition 21 Receives Patent For the Nutritional Treatment of Type 2 Diabetes; Patent Presents New Pharmaceutical Licensing Opportunities ConsumerLab.com Finds Most B-vitamin Supplements Contain What They Claim, But Often Exceed Safe Levels - Consumers Cautioned to Be Aware of Side Effects with High Dose Products Nutraceutix, Inc., Nutravite Announcement Commercial Availability of CDT™ Glucosamine for Canadian Marketplace Harvey Kamil Appointed President of NBTY, Inc. - Scott Rudolph to Continue as Chairman and CEO drugstore.com Expects to Reach Profitability Target in 2003 Human Genome Project Leads to Innovative Healthcare NPIcenter’s Career Center targets nutraceutical Industry Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders Adding Vitamin C To Certain Drugs May Help Treat Alzheimer's, Other Brain Disorders Editorial: An Exercise in Synergy NBTY, Inc. Appoints Harvey Kamil President, Scott Rudolph To Continue As Chairman And CEO Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids Ross Products to Launch Infant Formula Supplemented With Two New Fatty Acids LignisulMSM vs Naproxen for Osteoarthritis Clinical Trial Gets Underway Natural Health Trends Corp. Launches Lexxus Taiwan FDA Presents Compliance Guide for Structure/Function Claims New TrimFit® Bars Redefine Energy Bar Category New TrimFit® Bars Redefine Energy Bar Category Probiata® Offers Safe, Natural and Effective Alternative Alive & Well with Michelle Harris Be Well and Get Rewarded! Find Personalized Wellness Solutions and Earn Free Vitamins at NatureMade.com Consumers Search for Healthy Cleaning Products That Work Nordic Naturals: Omega 3 Fatty Acids Cyanotech Names Bob Capelli as Director of Sales SourceOne Announces Completion of Phase III of Sytrinol(TM) Long-Term Clinical Trial twelve week, double-blind, crossover design, randomized trial of 120 moderately hypercholesterolemic men and women now complete. SourceOne Announces Completion of Phase III of Sytrinol(TM) Long-Term Clinical Trial twelve week, double-blind, crossover design, randomized trial of 120 moderately hypercholesterolemic men and women now complete. SourceOne Announces Completion of Phase III of Sytrinol(TM) Long-Term Clinical Trial twelve week, double-blind, crossover design, randomized trial of 120 moderately hypercholesterolemic men and women now complete. SourceOne Announces Completion of Phase III of Sytrinol(TM) Long-Term Clinical Trial twelve week, double-blind, crossover design, randomized trial of 120 moderately hypercholesterolemic men and women now complete. SourceOne Announces Start of Clinical Trial for Sytrinol(TM) and Plant Sterol Combination Double-blind, placebo-controlled, randomized study will include several arms with a combination of Sytrinol™ and plant sterols, and will be conducted by Radiant Research Incorporated located in Chicago IL. SourceOne Announces Start of Clinical Trial for Sytrinol(TM) and Plant Sterol Combination Double-blind, placebo-controlled, randomized study will include several arms with a combination of Sytrinol™ and plant sterols, and will be conducted by Radiant Research Incorporated located in Chicago IL. Research Shows Product Shortens Duration of Common Cold Randomized, double-blind, placebo-controlled, multi-center study presented at the First International Conference on Natural Products and Molecular Therapy indicates that UMCKA(R) COLDCARE(TM), a proprietary medicine made from Pelargonium sidoides roots, significantly shortens duration and reduces severity of the common cold. Research Shows Product Shortens Duration of Common Cold Randomized, double-blind, placebo-controlled, multi-center study presented at the First International Conference on Natural Products and Molecular Therapy indicates that UMCKA(R) COLDCARE(TM), a proprietary medicine made from Pelargonium sidoides roots, significantly shortens duration and reduces severity of the common cold. Research Shows Product Shortens Duration of Common Cold Randomized, double-blind, placebo-controlled, multi-center study presented at the First International Conference on Natural Products and Molecular Therapy indicates that UMCKA(R) COLDCARE(TM), a proprietary medicine made from Pelargonium sidoides roots, significantly shortens duration and reduces severity of the common cold. Research Shows Product Shortens Duration of Common Cold Randomized, double-blind, placebo-controlled, multi-center study presented at the First International Conference on Natural Products and Molecular Therapy indicates that UMCKA(R) COLDCARE(TM), a proprietary medicine made from Pelargonium sidoides roots, significantly shortens duration and reduces severity of the common cold. Research Shows Product Shortens Duration of Common Cold Randomized, double-blind, placebo-controlled, multi-center study presented at the First International Conference on Natural Products and Molecular Therapy indicates that UMCKA(R) COLDCARE(TM), a proprietary medicine made from Pelargonium sidoides roots, significantly shortens duration and reduces severity of the common cold. Research Shows Product Shortens Duration of Common Cold Randomized, double-blind, placebo-controlled, multi-center study presented at the First International Conference on Natural Products and Molecular Therapy indicates that UMCKA(R) COLDCARE(TM), a proprietary medicine made from Pelargonium sidoides roots, significantly shortens duration and reduces severity of the common cold. Research Shows Product Shortens Duration of Common Cold Randomized, double-blind, placebo-controlled, multi-center study presented at the First International Conference on Natural Products and Molecular Therapy indicates that UMCKA(R) COLDCARE(TM), a proprietary medicine made from Pelargonium sidoides roots, significantly shortens duration and reduces severity of the common cold. Calcium and Vitamin D Most Effective for Treatment of Crohn's-related Bone Loss Study shows that calcium and vitamin D treatment alone can improve bone mineral density (BMD) in Crohn's patients by 3 to 4 percent per year; addition of popular bone building drugs to calcium and vitamin D therapy to treat bone loss associated with Crohn's disease is not beneficial. Calcium and Vitamin D Most Effective for Treatment of Crohn's-related Bone Loss Study shows that calcium and vitamin D treatment alone can improve bone mineral density (BMD) in Crohn's patients by 3 to 4 percent per year; addition of popular bone building drugs to calcium and vitamin D therapy to treat bone loss associated with Crohn's disease is not beneficial. Calcium and Vitamin D Most Effective for Treatment of Crohn's-related Bone Loss Study shows that calcium and vitamin D treatment alone can improve bone mineral density (BMD) in Crohn's patients by 3 to 4 percent per year; addition of popular bone building drugs to calcium and vitamin D therapy to treat bone loss associated with Crohn's disease is not beneficial. Calcium and Vitamin D Most Effective for Treatment of Crohn's-related Bone Loss Study shows that calcium and vitamin D treatment alone can improve bone mineral density (BMD) in Crohn's patients by 3 to 4 percent per year; addition of popular bone building drugs to calcium and vitamin D therapy to treat bone loss associated with Crohn's disease is not beneficial. Calcium and Vitamin D Most Effective for Treatment of Crohn's-related Bone Loss Study shows that calcium and vitamin D treatment alone can improve bone mineral density (BMD) in Crohn's patients by 3 to 4 percent per year; addition of popular bone building drugs to calcium and vitamin D therapy to treat bone loss associated with Crohn's disease is not beneficial. Calcium and Vitamin D Most Effective for Treatment of Crohn's-related Bone Loss Study shows that calcium and vitamin D treatment alone can improve bone mineral density (BMD) in Crohn's patients by 3 to 4 percent per year; addition of popular bone building drugs to calcium and vitamin D therapy to treat bone loss associated with Crohn's disease is not beneficial. U.S. Department of Defense University and Humanetics to Co-Develop Multiple Compounds Focus of new agreement is to develop and commercialize nutritional supplements and drugs that show promise in supporting and protecting the immune system against challenges from exposure to radiation U.S. Department of Defense University and Humanetics to Co-Develop Multiple Compounds Focus of new agreement is to develop and commercialize nutritional supplements and drugs that show promise in supporting and protecting the immune system against challenges from exposure to radiation Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort) Researchers note that half of those given St. John's wort for six weeks in this randomised double blind, reference controlled trial, reported an improvement in their symptoms, versus one third of those who took Seroxat. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort) Researchers note that half of those given St. John's wort for six weeks in this randomised double blind, reference controlled trial, reported an improvement in their symptoms, versus one third of those who took Seroxat. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort) Researchers note that half of those given St. John's wort for six weeks in this randomised double blind, reference controlled trial, reported an improvement in their symptoms, versus one third of those who took Seroxat. Advitech Completes Recruitment For Second Clinical Study on Oral Treatment For Psoriasis Eighty-four patients with mild to moderate psoriasis have been recruited; treatment phase is expected to be completed by the end of June and results should be made available in July. Advitech Completes Recruitment For Second Clinical Study on Oral Treatment For Psoriasis Eighty-four patients with mild to moderate psoriasis have been recruited; treatment phase is expected to be completed by the end of June and results should be made available in July. Advitech Completes Recruitment For Second Clinical Study on Oral Treatment For Psoriasis Eighty-four patients with mild to moderate psoriasis have been recruited; treatment phase is expected to be completed by the end of June and results should be made available in July. Advitech Completes Recruitment For Second Clinical Study on Oral Treatment For Psoriasis Eighty-four patients with mild to moderate psoriasis have been recruited; treatment phase is expected to be completed by the end of June and results should be made available in July. New Chromium Supplementation Clinical Trial Initiated - First to Study Effects in Overweight Children with Type 1 Diabetes Double-blind, randomized, placebo-controlled clinical trial to study the effects of chromium picolinate supplementation in overweight pediatric patients with poorly-controlled type 1 diabetes to be initiated at Childrens Hospital Los Angeles. New Chromium Supplementation Clinical Trial Initiated - First to Study Effects in Overweight Children with Type 1 Diabetes Double-blind, randomized, placebo-controlled clinical trial to study the effects of chromium picolinate supplementation in overweight pediatric patients with poorly-controlled type 1 diabetes to be initiated at Childrens Hospital Los Angeles. New Chromium Supplementation Clinical Trial Initiated - First to Study Effects in Overweight Children with Type 1 Diabetes Double-blind, randomized, placebo-controlled clinical trial to study the effects of chromium picolinate supplementation in overweight pediatric patients with poorly-controlled type 1 diabetes to be initiated at Childrens Hospital Los Angeles. New Chromium Supplementation Clinical Trial Initiated - First to Study Effects in Overweight Children with Type 1 Diabetes Double-blind, randomized, placebo-controlled clinical trial to study the effects of chromium picolinate supplementation in overweight pediatric patients with poorly-controlled type 1 diabetes to be initiated at Childrens Hospital Los Angeles. New Chromium Supplementation Clinical Trial Initiated - First to Study Effects in Overweight Children with Type 1 Diabetes Double-blind, randomized, placebo-controlled clinical trial to study the effects of chromium picolinate supplementation in overweight pediatric patients with poorly-controlled type 1 diabetes to be initiated at Childrens Hospital Los Angeles. St. John’s wort as Effective as Popular Prescription Anti-Depressant Organization comments on study published Friday February 13th in British Medical Journal. St. John’s wort as Effective as Popular Prescription Anti-Depressant Organization comments on study published Friday February 13th in British Medical Journal. Advitech and CHUL Research Center to Test XP-828L For the Treatment of Inflammatory Bowel Diseases Advitech and CHUL Research Center, CHULRC (CHUQ) will carry out a research project to assess the potential of XP-828L, a purified milk protein fraction with a patented growth factor composition, for treatment of inflammatory bowel diseases. Advitech and CHUL Research Center to Test XP-828L For the Treatment of Inflammatory Bowel Diseases Advitech and CHUL Research Center, CHULRC (CHUQ) will carry out a research project to assess the potential of XP-828L, a purified milk protein fraction with a patented growth factor composition, for treatment of inflammatory bowel diseases. Advitech and CHUL Research Center to Test XP-828L For the Treatment of Inflammatory Bowel Diseases Advitech and CHUL Research Center, CHULRC (CHUQ) will carry out a research project to assess the potential of XP-828L, a purified milk protein fraction with a patented growth factor composition, for treatment of inflammatory bowel diseases. Advitech and CHUL Research Center to Test XP-828L For the Treatment of Inflammatory Bowel Diseases Advitech and CHUL Research Center, CHULRC (CHUQ) will carry out a research project to assess the potential of XP-828L, a purified milk protein fraction with a patented growth factor composition, for treatment of inflammatory bowel diseases. Folic Acid May Prevent Hypertension in Addition to Reducing the Risk of Birth Defects JAMA study shows that for younger women who consume at least 1000 micrograms of folic acid the incidence of hypertension is decrased by 46%. Folic Acid May Prevent Hypertension in Addition to Reducing the Risk of Birth Defects JAMA study shows that for younger women who consume at least 1000 micrograms of folic acid the incidence of hypertension is decrased by 46%. Folic Acid May Prevent Hypertension in Addition to Reducing the Risk of Birth Defects JAMA study shows that for younger women who consume at least 1000 micrograms of folic acid the incidence of hypertension is decrased by 46%. Folic Acid May Prevent Hypertension in Addition to Reducing the Risk of Birth Defects JAMA study shows that for younger women who consume at least 1000 micrograms of folic acid the incidence of hypertension is decrased by 46%. Poor Prenatal Nutrition Permanently Damages Function of Insulin-producing Cells in the Pancreas Mice studies indicate that poor prenatal nutrition impairs the pancreas's ability to later secrete enough insulin in response to blood glucose, leading to elevated risk of Type 2 diabetes later in life. Poor Prenatal Nutrition Permanently Damages Function of Insulin-producing Cells in the Pancreas Mice studies indicate that poor prenatal nutrition impairs the pancreas's ability to later secrete enough insulin in response to blood glucose, leading to elevated risk of Type 2 diabetes later in life. Poor Prenatal Nutrition Permanently Damages Function of Insulin-producing Cells in the Pancreas Mice studies indicate that poor prenatal nutrition impairs the pancreas's ability to later secrete enough insulin in response to blood glucose, leading to elevated risk of Type 2 diabetes later in life. Poor Prenatal Nutrition Permanently Damages Function of Insulin-producing Cells in the Pancreas Mice studies indicate that poor prenatal nutrition impairs the pancreas's ability to later secrete enough insulin in response to blood glucose, leading to elevated risk of Type 2 diabetes later in life. Poor Prenatal Nutrition Permanently Damages Function of Insulin-producing Cells in the Pancreas Mice studies indicate that poor prenatal nutrition impairs the pancreas's ability to later secrete enough insulin in response to blood glucose, leading to elevated risk of Type 2 diabetes later in life. Study Results Show Efficacy of Bioforce’s Prostasan Swiss study of 364 men indicates reduction of symptoms. Study Results Show Efficacy of Bioforce’s Prostasan Swiss study of 364 men indicates reduction of symptoms. Study Results Show Efficacy of Bioforce’s Prostasan Swiss study of 364 men indicates reduction of symptoms. Study Results Show Efficacy of Bioforce’s Prostasan Swiss study of 364 men indicates reduction of symptoms. Scientific Experts Meet to Discuss Safety and Benefits of Vitamin E Group concluded that antioxidant supplements are safe and appear to confer a health benefit in certain individuals; Future research in well-defined populations with both clinical and biomarker end-points needs to be undertaken. Scientific Experts Meet to Discuss Safety and Benefits of Vitamin E Group concluded that antioxidant supplements are safe and appear to confer a health benefit in certain individuals; Future research in well-defined populations with both clinical and biomarker end-points needs to be undertaken. Scientific Experts Meet to Discuss Safety and Benefits of Vitamin E Group concluded that antioxidant supplements are safe and appear to confer a health benefit in certain individuals; Future research in well-defined populations with both clinical and biomarker end-points needs to be undertaken. Scientific Experts Meet to Discuss Safety and Benefits of Vitamin E Group concluded that antioxidant supplements are safe and appear to confer a health benefit in certain individuals; Future research in well-defined populations with both clinical and biomarker end-points needs to be undertaken. Scientific Experts Meet to Discuss Safety and Benefits of Vitamin E Group concluded that antioxidant supplements are safe and appear to confer a health benefit in certain individuals; Future research in well-defined populations with both clinical and biomarker end-points needs to be undertaken. Scientific Experts Meet to Discuss Safety and Benefits of Vitamin E Group concluded that antioxidant supplements are safe and appear to confer a health benefit in certain individuals; Future research in well-defined populations with both clinical and biomarker end-points needs to be undertaken. COLD-fX(R) to be Studied as New Way to Protect Seniors from Influenza in Canadian Nursing Homes Company announces partnership project to investigate the potential use of COLD-fX(R) as a "standard of care" for the prevention of upper respiratory infections in Canadian nursing homes. COLD-fX(R) to be Studied as New Way to Protect Seniors from Influenza in Canadian Nursing Homes Company announces partnership project to investigate the potential use of COLD-fX(R) as a "standard of care" for the prevention of upper respiratory infections in Canadian nursing homes. COLD-fX(R) to be Studied as New Way to Protect Seniors from Influenza in Canadian Nursing Homes Company announces partnership project to investigate the potential use of COLD-fX(R) as a "standard of care" for the prevention of upper respiratory infections in Canadian nursing homes. COLD-fX(R) to be Studied as New Way to Protect Seniors from Influenza in Canadian Nursing Homes Company announces partnership project to investigate the potential use of COLD-fX(R) as a "standard of care" for the prevention of upper respiratory infections in Canadian nursing homes. New Study Shows GliSODin(R) Inhibits DNA Damage Due to Ischemia-reperfusion Induced Oxidative Stress German researchers conclude that pretreatment with GliSODin inhibits oxidative DNA damage related to induced ischemia-reperfusion injury. New Study Shows GliSODin(R) Inhibits DNA Damage Due to Ischemia-reperfusion Induced Oxidative Stress German researchers conclude that pretreatment with GliSODin inhibits oxidative DNA damage related to induced ischemia-reperfusion injury. New Study Shows GliSODin(R) Inhibits DNA Damage Due to Ischemia-reperfusion Induced Oxidative Stress German researchers conclude that pretreatment with GliSODin inhibits oxidative DNA damage related to induced ischemia-reperfusion injury. New Study Shows GliSODin(R) Inhibits DNA Damage Due to Ischemia-reperfusion Induced Oxidative Stress German researchers conclude that pretreatment with GliSODin inhibits oxidative DNA damage related to induced ischemia-reperfusion injury. Effect of Folate and Mecobalamin on Hip Fractures in Patients With Stroke Study shows that folate and vitamin B12 reduce risk of hip fracture in elderly patients. Effect of Folate and Mecobalamin on Hip Fractures in Patients With Stroke Study shows that folate and vitamin B12 reduce risk of hip fracture in elderly patients. Effect of Folate and Mecobalamin on Hip Fractures in Patients With Stroke Study shows that folate and vitamin B12 reduce risk of hip fracture in elderly patients. Effect of Folate and Mecobalamin on Hip Fractures in Patients With Stroke Study shows that folate and vitamin B12 reduce risk of hip fracture in elderly patients. Fluxome and GlycaNova Join Forces to Bring a Promising Beta Glucan Product to the US Dietary Supplement Market Nutraceutical ingredient provider Fluxome A/S has entered a strategic exclusivity agreement with research-based biotechnology company GlycaNova Norway AS. Fluxome gains the exclusive rights from GlycaNova to market and sell a very promising beta glucan product in the US dietary supplement market. Fluxome and GlycaNova Join Forces to Bring a Promising Beta Glucan Product to the US Dietary Supplement Market Nutraceutical ingredient provider Fluxome A/S has entered a strategic exclusivity agreement with research-based biotechnology company GlycaNova Norway AS. Fluxome gains the exclusive rights from GlycaNova to market and sell a very promising beta glucan product in the US dietary supplement market. Fluxome and GlycaNova Join Forces to Bring a Promising Beta Glucan Product to the US Dietary Supplement Market Nutraceutical ingredient provider Fluxome A/S has entered a strategic exclusivity agreement with research-based biotechnology company GlycaNova Norway AS. Fluxome gains the exclusive rights from GlycaNova to market and sell a very promising beta glucan product in the US dietary supplement market. Fluxome and GlycaNova Join Forces to Bring a Promising Beta Glucan Product to the US Dietary Supplement Market Nutraceutical ingredient provider Fluxome A/S has entered a strategic exclusivity agreement with research-based biotechnology company GlycaNova Norway AS. Fluxome gains the exclusive rights from GlycaNova to market and sell a very promising beta glucan product in the US dietary supplement market. Fluxome and GlycaNova Join Forces to Bring a Promising Beta Glucan Product to the US Dietary Supplement Market Nutraceutical ingredient provider Fluxome A/S has entered a strategic exclusivity agreement with research-based biotechnology company GlycaNova Norway AS. Fluxome gains the exclusive rights from GlycaNova to market and sell a very promising beta glucan product in the US dietary supplement market. Fluxome and GlycaNova Join Forces to Bring a Promising Beta Glucan Product to the US Dietary Supplement Market Nutraceutical ingredient provider Fluxome A/S has entered a strategic exclusivity agreement with research-based biotechnology company GlycaNova Norway AS. Fluxome gains the exclusive rights from GlycaNova to market and sell a very promising beta glucan product in the US dietary supplement market. Fluxome and GlycaNova Join Forces to Bring a Promising Beta Glucan Product to the US Dietary Supplement Market Nutraceutical ingredient provider Fluxome A/S has entered a strategic exclusivity agreement with research-based biotechnology company GlycaNova Norway AS. Fluxome gains the exclusive rights from GlycaNova to market and sell a very promising beta glucan product in the US dietary supplement market. Fluxome and GlycaNova Join Forces to Bring a Promising Beta Glucan Product to the US Dietary Supplement Market Nutraceutical ingredient provider Fluxome A/S has entered a strategic exclusivity agreement with research-based biotechnology company GlycaNova Norway AS. Fluxome gains the exclusive rights from GlycaNova to market and sell a very promising beta glucan product in the US dietary supplement market. Fluxome and GlycaNova Join Forces to Bring a Promising Beta Glucan Product to the US Dietary Supplement Market Nutraceutical ingredient provider Fluxome A/S has entered a strategic exclusivity agreement with research-based biotechnology company GlycaNova Norway AS. Fluxome gains the exclusive rights from GlycaNova to market and sell a very promising beta glucan product in the US dietary supplement market. Fluxome and GlycaNova Join Forces to Bring a Promising Beta Glucan Product to the US Dietary Supplement Market Nutraceutical ingredient provider Fluxome A/S has entered a strategic exclusivity agreement with research-based biotechnology company GlycaNova Norway AS. Fluxome gains the exclusive rights from GlycaNova to market and sell a very promising beta glucan product in the US dietary supplement market. Fluxome and GlycaNova Join Forces to Bring a Promising Beta Glucan Product to the US Dietary Supplement Market Nutraceutical ingredient provider Fluxome A/S has entered a strategic exclusivity agreement with research-based biotechnology company GlycaNova Norway AS. Fluxome gains the exclusive rights from GlycaNova to market and sell a very promising beta glucan product in the US dietary supplement market. AHP Releases Monograph Standards on Stinging Nettle Root (Urtica dioica L.) The American Herbal Pharmacopoeia® (AHP), a California-based non-profit research organization, has released its quality control standards and therapeutic compendium for the popular botanical dietary supplement Stinging Nettle Root (Urtica dioica L.) AHP Releases Monograph Standards on Stinging Nettle Root (Urtica dioica L.) The American Herbal Pharmacopoeia® (AHP), a California-based non-profit research organization, has released its quality control standards and therapeutic compendium for the popular botanical dietary supplement Stinging Nettle Root (Urtica dioica L.) AHP Releases Monograph Standards on Stinging Nettle Root (Urtica dioica L.) The American Herbal Pharmacopoeia® (AHP), a California-based non-profit research organization, has released its quality control standards and therapeutic compendium for the popular botanical dietary supplement Stinging Nettle Root (Urtica dioica L.) AHP Releases Monograph Standards on Stinging Nettle Root (Urtica dioica L.) The American Herbal Pharmacopoeia® (AHP), a California-based non-profit research organization, has released its quality control standards and therapeutic compendium for the popular botanical dietary supplement Stinging Nettle Root (Urtica dioica L.) AHP Releases Monograph Standards on Stinging Nettle Root (Urtica dioica L.) The American Herbal Pharmacopoeia® (AHP), a California-based non-profit research organization, has released its quality control standards and therapeutic compendium for the popular botanical dietary supplement Stinging Nettle Root (Urtica dioica L.) AHP Releases Monograph Standards on Stinging Nettle Root (Urtica dioica L.) The American Herbal Pharmacopoeia® (AHP), a California-based non-profit research organization, has released its quality control standards and therapeutic compendium for the popular botanical dietary supplement Stinging Nettle Root (Urtica dioica L.) AHP Releases Monograph Standards on Stinging Nettle Root (Urtica dioica L.) The American Herbal Pharmacopoeia® (AHP), a California-based non-profit research organization, has released its quality control standards and therapeutic compendium for the popular botanical dietary supplement Stinging Nettle Root (Urtica dioica L.) AHP Releases Monograph Standards on Stinging Nettle Root (Urtica dioica L.) The American Herbal Pharmacopoeia® (AHP), a California-based non-profit research organization, has released its quality control standards and therapeutic compendium for the popular botanical dietary supplement Stinging Nettle Root (Urtica dioica L.) AHP Releases Monograph Standards on Stinging Nettle Root (Urtica dioica L.) The American Herbal Pharmacopoeia® (AHP), a California-based non-profit research organization, has released its quality control standards and therapeutic compendium for the popular botanical dietary supplement Stinging Nettle Root (Urtica dioica L.) Rudi's Organic Bakery Unveils New Brand and Packaging at Natural Products Expo West Rudi's Organic Bakery, Inc. has unveiled its new brand identity and packaging at the annual Natural Products Expo West in Anaheim, Calif. Rudi's Organic Bakery Unveils New Brand and Packaging at Natural Products Expo West Rudi's Organic Bakery, Inc. has unveiled its new brand identity and packaging at the annual Natural Products Expo West in Anaheim, Calif. Rudi's Organic Bakery Unveils New Brand and Packaging at Natural Products Expo West Rudi's Organic Bakery, Inc. has unveiled its new brand identity and packaging at the annual Natural Products Expo West in Anaheim, Calif. Rudi's Organic Bakery Unveils New Brand and Packaging at Natural Products Expo West Rudi's Organic Bakery, Inc. has unveiled its new brand identity and packaging at the annual Natural Products Expo West in Anaheim, Calif. Rudi's Organic Bakery Unveils New Brand and Packaging at Natural Products Expo West Rudi's Organic Bakery, Inc. has unveiled its new brand identity and packaging at the annual Natural Products Expo West in Anaheim, Calif. Rudi's Organic Bakery Unveils New Brand and Packaging at Natural Products Expo West Rudi's Organic Bakery, Inc. has unveiled its new brand identity and packaging at the annual Natural Products Expo West in Anaheim, Calif. Rudi's Organic Bakery Unveils New Brand and Packaging at Natural Products Expo West Rudi's Organic Bakery, Inc. has unveiled its new brand identity and packaging at the annual Natural Products Expo West in Anaheim, Calif. Rudi's Organic Bakery Unveils New Brand and Packaging at Natural Products Expo West Rudi's Organic Bakery, Inc. has unveiled its new brand identity and packaging at the annual Natural Products Expo West in Anaheim, Calif. Rudi's Organic Bakery Unveils New Brand and Packaging at Natural Products Expo West Rudi's Organic Bakery, Inc. has unveiled its new brand identity and packaging at the annual Natural Products Expo West in Anaheim, Calif. Senators reach agreement on dietary supplement legislation Several weeks ago, Senators McCain and Dorgan introduced S. 3002, the Dietary Supplement Safety Act of 2010, stirring up vocal industry reaction at what it felt was 'over the top' regulation. Last week, Senator McCain withdrew support for his own bill. Senators reach agreement on dietary supplement legislation Several weeks ago, Senators McCain and Dorgan introduced S. 3002, the Dietary Supplement Safety Act of 2010, stirring up vocal industry reaction at what it felt was 'over the top' regulation. Last week, Senator McCain withdrew support for his own bill. Senators reach agreement on dietary supplement legislation Several weeks ago, Senators McCain and Dorgan introduced S. 3002, the Dietary Supplement Safety Act of 2010, stirring up vocal industry reaction at what it felt was 'over the top' regulation. Last week, Senator McCain withdrew support for his own bill. Senators reach agreement on dietary supplement legislation Several weeks ago, Senators McCain and Dorgan introduced S. 3002, the Dietary Supplement Safety Act of 2010, stirring up vocal industry reaction at what it felt was 'over the top' regulation. Last week, Senator McCain withdrew support for his own bill. Senators reach agreement on dietary supplement legislation Several weeks ago, Senators McCain and Dorgan introduced S. 3002, the Dietary Supplement Safety Act of 2010, stirring up vocal industry reaction at what it felt was 'over the top' regulation. Last week, Senator McCain withdrew support for his own bill. Senators reach agreement on dietary supplement legislation Several weeks ago, Senators McCain and Dorgan introduced S. 3002, the Dietary Supplement Safety Act of 2010, stirring up vocal industry reaction at what it felt was 'over the top' regulation. Last week, Senator McCain withdrew support for his own bill.	BENICIA, Calif., Feb 18, 2005 /PRNewswire via COMTEX/ -- InterHealth Nutraceuticals today announced that a multicenter clinical trial spanning three years and involving 545 patients in 14 clinical centers has confirmed the safety and efficacy of Aller-7(R) in people with allergic rhinitis (airborne allergies). Aller-7 is a patented nutritional ingredient marketed by InterHealth Nutraceuticals, Inc., available in a wide variety of dietary supplements sold in natural health stores. The study, published in the "International Journal of Clinical Pharmacology Research" (XXIV (2/3): 79-94, 2004), found that over a period of 12 weeks, 94% of patients in open label trials and 92% of patients in double-blind, placebo-controlled trials treated with Aller-7 reported an improvement in symptoms ranging from more than 40 to 100 percent. Complete relief from sneezing, running nose and nasal congestion in open label trials was seen in 28 percent, 37 percent and 45 percent of patients, respectively. "This major clinical milestone provides further confirmation of the efficacy and safety of Aller-7," stated Dr. V.S. Saxena, the study director at the Clinical Research Division of ASA Foundation, which coordinated the studies. "Aller-7 can safely provide the symptomatic relief that allows airborne allergy sufferers to regain quality of life and overall function." According to Dr. Saxena, significant improvement was also observed in absolute eosinophil count, mucociliary clearance time and peak nasal flow rate, providing objective support to the patients' experiences. No serious side-effects were observed, thus demonstrating that Aller-7 is both well tolerated and efficacious in combating the symptoms of airborne allergies. Airborne allergies affect more than 40 million people in U.S., who spend in excess of $4.5 billion annually in search of relief. The initial stages of allergic rhinitis are seasonal in nature, but often become perennial. The most common allergens include household dust, dust mites, pet dander and pollens. "Given the prevalence of airborne allergies and the attendant side-effects of many medications, all-natural Aller-7 is being embraced by consumers," stated William "Skip" Seroy, president of InterHealth. "For many, side-effects of these medications, such as nervousness, headache, fatigue and drowsiness, are worse than the symptoms themselves. Aller-7 is taken as a dietary supplement before allergy season starts or even all year round, if perennial breathing difficulties are a problem, making it an ideal long-term solution without any of those debilitating side effects." According to Seroy, no other all-natural allergy product has been as extensively tested as Aller-7. "The multicenter clinical trial on Aller-7 not only sets a research standard for all-natural allergy relief, but for natural products as a whole," stated Seroy. More than 10 years in the making, Aller-7 is a patented blend of seven herbal extracts, including Phyllanthus emblica (fruit), Terminalia chebula (fruit), Terminalia bellerica (fruit), Albizia lebbeck (bark), Zingiber officinale (root), Piper longum (fruit) and Piper nigrum (fruit). Made by a unique three-step extraction process, Aller-7 contains standardized levels of polyphenols, chebulic acid, glycosides, piperine, gallic acid, ellagic acid and gingerols. Aller-7 is patented under U.S. Patent 6,730,332 with worldwide patents pending. Aller-7 was developed by Natural Remedies Ltd, Bangalore, India and is sold by InterHealth Nutraceuticals as an ingredient to manufacturers of dietary supplements. The Aller-7 ingredient can be found in many popular brands and is sold almost exclusively in natural health stores. Consumers can identify products that contain Aller-7 by looking for the Aller-7 logo on the label. About InterHealth Nutraceuticals, Inc. InterHealth Nutraceuticals researches, develops, markets and distributes specialty nutritional ingredients, which are sold worldwide to manufacturers of dietary supplements and nutraceutical food and beverage products. In addition to Aller-7(R), the company's products include SuperCitriMax(R), ChromeMate(R), OptiBery(R), UC-II(TM), L-OptiZinc(R) and Protykin(R). For more information about InterHealth and its products, call 1-800-783-4636 or 1-707-751-2800 (outside U.S) or visit the website at www.InterHealthUSA.com.
Powered By Traffic Booster Absolute News Manager Plug-in by Xigla Software